Literature DB >> 29861178

Identification of human vaccinees that possess antibodies targeting the egg-adapted hemagglutinin receptor binding site of an H1N1 influenza vaccine strain.

Tyler A Garretson1, Joshua G Petrie2, Emily T Martin2, Arnold S Monto2, Scott E Hensley3.   

Abstract

Human influenza viruses passaged in eggs often acquire mutations in the hemagglutinin (HA) receptor binding site (RBS). To determine if egg-adapted H1N1 vaccines commonly elicit antibodies targeting the egg-adapted RBS of HA, we completed hemagglutinin-inhibition assays with A/California/7/2009 HA and egg-adapted A/California/7/2009-X-179A HA using sera collected from 159 humans vaccinated with seasonal influenza vaccines during the 2015-16 season. We found that ∼5% of participants had ≥4-fold higher antibody titers to the egg-adapted viral strain compared to wild type viral strain. We used reverse-genetics to demonstrate that a single egg-adapted HA RBS mutation (Q226R) was responsible for this phenotype.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Hemagglutinin; Influenza; Vaccines

Mesh:

Substances:

Year:  2018        PMID: 29861178      PMCID: PMC5995672          DOI: 10.1016/j.vaccine.2018.05.086

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  15 in total

Review 1.  Influenza vaccines: the good, the bad, and the eggs.

Authors:  Stacey Schultz-Cherry; Jeremy C Jones
Journal:  Adv Virus Res       Date:  2010       Impact factor: 9.937

2.  Single hemagglutinin mutations that alter both antigenicity and receptor binding avidity influence influenza virus antigenic clustering.

Authors:  Yang Li; David L Bostick; Colleen B Sullivan; Jaclyn L Myers; Sara B Griesemer; Kirsten Stgeorge; Joshua B Plotkin; Scott E Hensley
Journal:  J Virol       Date:  2013-07-03       Impact factor: 5.103

3.  Elicitation of anti-1918 influenza virus immunity early in life prevents morbidity and lower levels of lung infection by 2009 pandemic H1N1 influenza virus in aged mice.

Authors:  Brendan M Giles; Stephanie J Bissel; Jodi K Craigo; Dilhari R Dealmeida; Clayton A Wiley; Terrence M Tumpey; Ted M Ross
Journal:  J Virol       Date:  2011-11-30       Impact factor: 5.103

4.  Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin.

Authors:  James R R Whittle; Ruijun Zhang; Surender Khurana; Lisa R King; Jody Manischewitz; Hana Golding; Philip R Dormitzer; Barton F Haynes; Emmanuel B Walter; M Anthony Moody; Thomas B Kepler; Hua-Xin Liao; Stephen C Harrison
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-08       Impact factor: 11.205

Review 5.  A Perspective on the Structural and Functional Constraints for Immune Evasion: Insights from Influenza Virus.

Authors:  Nicholas C Wu; Ian A Wilson
Journal:  J Mol Biol       Date:  2017-06-23       Impact factor: 5.469

6.  Recent H3N2 influenza virus clinical isolates rapidly acquire hemagglutinin or neuraminidase mutations when propagated for antigenic analyses.

Authors:  Benjamin S Chambers; Yang Li; Richard L Hodinka; Scott E Hensley
Journal:  J Virol       Date:  2014-07-02       Impact factor: 5.103

7.  Substantial Influenza Vaccine Effectiveness in Households With Children During the 2013-2014 Influenza Season, When 2009 Pandemic Influenza A(H1N1) Virus Predominated.

Authors:  Suzanne E Ohmit; Joshua G Petrie; Ryan E Malosh; Emileigh Johnson; Rachel Truscon; Barbara Aaron; Casey Martens; Caroline Cheng; Alicia M Fry; Arnold S Monto
Journal:  J Infect Dis       Date:  2015-11-23       Impact factor: 5.226

Review 8.  Advances in universal influenza virus vaccine design and antibody mediated therapies based on conserved regions of the hemagglutinin.

Authors:  Florian Krammer; Peter Palese; John Steel
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

9.  The Household Influenza Vaccine Effectiveness Study: Lack of Antibody Response and Protection Following Receipt of 2014-2015 Influenza Vaccine.

Authors:  Joshua G Petrie; Ryan E Malosh; Caroline K Cheng; Suzanne E Ohmit; Emily T Martin; Emileigh Johnson; Rachel Truscon; Maryna C Eichelberger; Larisa V Gubareva; Alicia M Fry; Arnold S Monto
Journal:  Clin Infect Dis       Date:  2017-10-30       Impact factor: 9.079

10.  Antibodies Against the Current Influenza A(H1N1) Vaccine Strain Do Not Protect Some Individuals From Infection With Contemporary Circulating Influenza A(H1N1) Virus Strains.

Authors:  Joshua G Petrie; Kaela Parkhouse; Suzanne E Ohmit; Ryan E Malosh; Arnold S Monto; Scott E Hensley
Journal:  J Infect Dis       Date:  2016-10-07       Impact factor: 7.759

View more
  4 in total

1.  A single-shot adenoviral vaccine provides hemagglutinin stalk-mediated protection against heterosubtypic influenza challenge in mice.

Authors:  Carly M Bliss; Alec W Freyn; Tom G Caniels; Victor H Leyva-Grado; Raffael Nachbagauer; Weina Sun; Gene S Tan; Virginia L Gillespie; Meagan McMahon; Florian Krammer; Adrian V S Hill; Peter Palese; Lynda Coughlan
Journal:  Mol Ther       Date:  2022-01-07       Impact factor: 12.910

Review 2.  Challenges of Making Effective Influenza Vaccines.

Authors:  Sigrid Gouma; Elizabeth M Anderson; Scott E Hensley
Journal:  Annu Rev Virol       Date:  2020-05-11       Impact factor: 10.431

3.  Differential disease severity and whole-genome sequence analysis for human influenza A/H1N1pdm virus in 2015-2016 influenza season.

Authors:  Hsuan Liu; Yu-Nong Gong; Kathryn Shaw-Saliba; Thomas Mehoke; Jared Evans; Zhen-Ying Liu; Mitra Lewis; Lauren Sauer; Peter Thielen; Richard Rothman; Kuan-Fu Chen; Andrew Pekosz
Journal:  Virus Evol       Date:  2021-05-18

4.  An Egg-Derived Sulfated N-Acetyllactosamine Glycan Is an Antigenic Decoy of Influenza Virus Vaccines.

Authors:  Jenna J Guthmiller; Henry A Utset; Carole Henry; Lei Li; Nai-Ying Zheng; Weina Sun; Marcos Costa Vieira; Seth Zost; Min Huang; Scott E Hensley; Sarah Cobey; Peter Palese; Patrick C Wilson
Journal:  mBio       Date:  2021-06-15       Impact factor: 7.867

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.